Search: onr:"swepub:oai:DiVA.org:uu-123999" >
Cancer risk in pati...
-
Askling, JohanKarolinska Institutet
(author)
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies : does the risk change with the time since start of treatment?
- Article/chapterEnglish2009
Publisher, publication year, extent ...
-
2009-10-29
-
Wiley,2009
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-123999
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-123999URI
-
https://doi.org/10.1002/art.24941DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-30993URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-52389URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:119595041URI
-
https://lup.lub.lu.se/record/1519632URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVE:To determine the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor alpha (anti-TNFalpha) therapies that have proven effective in the treatment of chronic inflammatory conditions.METHODS:By linking together data from the Swedish Biologics Register, Swedish registers of RA, and the Swedish Cancer Register, we identified and analyzed for cancer occurrence a national cohort of 6,366 patients with RA who first started anti-TNF therapy between January 1999 and July 2006. As comparators, we used a national biologics-naive RA cohort (n = 61,160), a cohort of RA patients newly starting methotrexate (n = 5,989), a cohort of RA patients newly starting disease-modifying antirheumatic drug combination therapy (n = 1,838), and the general population of Sweden. Relative risks (RRs) were estimated using Cox regression analyses, examining overall RR as well as RR by time since the first start of anti-TNF therapy, by the duration of active anti-TNF therapy, and by the anti-TNF agent received.RESULTS:During 25,693 person-years of followup in 6,366 patients newly starting anti-TNF, 240 first cancers occurred, yielding an RR of 1.00 (95% confidence interval 0.86-1.15) versus the biologics-naive RA cohort, and similar RRs versus the other 2 RA comparators. RRs did not increase with increasing time since the start of anti-TNF therapy, nor with the cumulative duration of active anti-TNF therapy. During the first year following the first treatment start, but not thereafter, dissimilar cancer risks for adalimumab, etanercept, and infliximab were observed.CONCLUSION:During the first 6 years after the start of anti-TNF therapy in routine care, no overall elevation of cancer risk and no increase with followup time were observed.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
van Vollenhoven, Ronald F.Karolinska Institutet
(author)
-
Granath, FredrikKarolinska Institutet
(author)
-
Raaschou, PaulineKarolinska Institutet
(author)
-
Fored, C. MichaelKarolinska Institutet
(author)
-
Baecklund, EvaUppsala universitet,Reumatologi,Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)evaba786
(author)
-
Dackhammar, ChristinaSahlgrenska University Hospital, Gothenburg, Sweden
(author)
-
Feltelius, NilsKarolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden, and Medical Products Agency, Uppsala, Sweden,Medical Products Agency, Uppsala, Sweden
(author)
-
Cöster, LarsÖstergötlands Läns Landsting,Linköpings universitet,Reumatologi,Hälsouniversitetet,Länskliniken för Reumatologi i Östergötland(Swepub:liu)larco79
(author)
-
Geborek, PierreLund University Hospital, Lund, Sweden
(author)
-
Jacobsson, LennartLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)orto-lja
(author)
-
Lindblad, StaffanKarolinska Institutet
(author)
-
Rantapää-Dahlqvist, Solbritt,1947-Umeå universitet,Reumatologi,Norrland University Hospital, Umeå, Sweden(Swepub:umu)sora0001
(author)
-
Saxne, ToreLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)reum-tsa
(author)
-
Klareskog, LarsKarolinska Institutet
(author)
-
Karolinska InstitutetReumatologi
(creator_code:org_t)
Related titles
-
In:Arthritis and Rheumatism: Wiley60:11, s. 3180-31890004-35911529-0131
Internet link
Find in a library
To the university's database
- By the author/editor
-
Askling, Johan
-
van Vollenhoven, ...
-
Granath, Fredrik
-
Raaschou, Paulin ...
-
Fored, C. Michae ...
-
Baecklund, Eva
-
show more...
-
Dackhammar, Chri ...
-
Feltelius, Nils
-
Cöster, Lars
-
Geborek, Pierre
-
Jacobsson, Lenna ...
-
Lindblad, Staffa ...
-
Rantapää-Dahlqvi ...
-
Saxne, Tore
-
Klareskog, Lars
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
Arthritis and Rh ...
- By the university
-
Uppsala University
-
Umeå University
-
Linköping University
-
Karolinska Institutet
-
Lund University